Skip to main content
Clinical Trials/NCT02569814
NCT02569814
Completed
Phase 1

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

Boryung Pharmaceutical Co., Ltd1 site in 1 country100 target enrollmentSeptember 2015

Overview

Phase
Phase 1
Intervention
Fimasartan/Amlodipine/Rosuvastatin
Conditions
Hypertension
Sponsor
Boryung Pharmaceutical Co., Ltd
Enrollment
100
Locations
1
Primary Endpoint
AUCt(Area Under the Curve) of Fimasartan, Amlodipine and Rosuvastatin
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

A Open-label, Randomized, Single-dose, 2x2 Crossover Study to Compare the Pharmacokinetics and Safety between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin versus Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects.

Registry
clinicaltrials.gov
Start Date
September 2015
End Date
December 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • a Healthy male subject, aged 19- 50 years

Exclusion Criteria

  • History of clinically significant hypersensitivity to study drug, any other drug
  • Hypotension or hypertension
  • Active liver disease
  • History of gastrointestinal disease
  • History of excessive alcohol abuse
  • Participation in any other study within 3 months

Arms & Interventions

Group 1

Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.

Intervention: Fimasartan/Amlodipine/Rosuvastatin

Group 1

Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.

Intervention: Fimasartan/Amlodipine

Group 1

Subjects of Group 1 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 1 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 15th day.

Intervention: Rosuvastatin

Group 2

Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.

Intervention: Fimasartan/Amlodipine/Rosuvastatin

Group 2

Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.

Intervention: Fimasartan/Amlodipine

Group 2

Subjects of Group 2 take a Fimasartan/Amlodipine/Rosuvastatin Combination Tablet at 1st day as period I. And then, after wash out for 2 weeks, as period II, subjects of Group 2 take Fimasartan/Amlodipine Combination Tablet and Rosuvastatin Individual Tablets at 15th day.

Intervention: Rosuvastatin

Outcomes

Primary Outcomes

AUCt(Area Under the Curve) of Fimasartan, Amlodipine and Rosuvastatin

Time Frame: 0~144 hour after medication

Cmax of Fimasartan, Amlodipine and Rosuvastatin

Time Frame: 0~144 hour after medication

Study Sites (1)

Loading locations...

Similar Trials